NASDAQ:RDUS - Radius Health Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.43 -0.24 (-1.29 %)
(As of 03/20/2019 04:00 PM ET)
Previous Close$18.67
Today's Range$18.37 - $19.00
52-Week Range$12.81 - $37.66
Volume410,406 shs
Average Volume568,173 shs
Market Capitalization$843.17 million
P/E Ratio-3.78
Dividend YieldN/A
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide that is in Phase III clinical trial to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator that is in Phase I clinical trial to treat breast cancer. The company has collaborations and license agreements with 3M; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited, as well as research and development agreements with Nordic Bioscience Clinical Development VII A/S. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RDUS



Sales & Book Value

Annual Sales$99.24 million
Book Value$1.33 per share


Net Income$-221,340,000.00
Net Margins-223.03%


Market Cap$843.17 million
Next Earnings Date5/9/2019 (Estimated)

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) posted its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.99) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($1.35) by $0.36. The biopharmaceutical company earned $22.63 million during the quarter, compared to analyst estimates of $20.84 million. Radius Health had a negative return on equity of 168.62% and a negative net margin of 223.03%. View Radius Health's Earnings History.

When is Radius Health's next earnings date?

Radius Health is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Radius Health.

What guidance has Radius Health issued on next quarter's earnings?

Radius Health updated its FY 2019 earnings guidance on Thursday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $155-175 million, compared to the consensus revenue estimate of $172.09 million.

What price target have analysts set for RDUS?

8 brokerages have issued 1 year price objectives for Radius Health's shares. Their forecasts range from $22.00 to $59.00. On average, they expect Radius Health's stock price to reach $45.1429 in the next twelve months. This suggests a possible upside of 144.9% from the stock's current price. View Analyst Price Targets for Radius Health.

What is the consensus analysts' recommendation for Radius Health?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Radius Health.

What are Wall Street analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:
  • 1. HC Wainwright analysts commented, "Valuation Our $22 price target for Radius is based on our sum of the parts NPV valuation based on each of the company’s ongoing products. Our DCF model utilizes a discount rate of 10.1% based on the company’s WACC (Beta of 1.1, equity risk premium of 6.7%)." (2/14/2019)
  • 2. According to Zacks Investment Research, "Radius got a boost with the approval of lead drug Tymlos. Sales of Tymlos continue to gain traction. Total prescriptions accounted for 22% of total U.S. anabolic osteoporosis market (based on Patient Months on Therapy, TRx PMOT) in the quarter. However, Radius suffered a setback when the CHMP communicated a negative trend vote for the MAA following a re-examination procedure of lead drug Tymlos. Thereafter, the CHMP communicated that it maintained its negative opinion on the MAA at its formal final vote. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded given the presence of products like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry in the last six months." (1/17/2019)
  • 3. Cantor Fitzgerald analysts commented, "TYMLOS Growing the Market. RDUS reported 1Q18 sales of $14.5 mln, up from $7.7 in the prior quarter. The launch is modest, which is not surprising given the specialty market and reimbursement/coverage ramp. What is a positive dynamic, in our view, is the market growth overall, with TYMLOS both capturing market share and growing the market overall for anabolics." (5/11/2018)

Has Radius Health been receiving favorable news coverage?

Headlines about RDUS stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Radius Health earned a news impact score of 1.3 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the next few days.

Who are some of Radius Health's key competitors?

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include Gilead Sciences (GILD), Opko Health (OPK), Celgene (CELG), Micron Technology (MU), Allergan (AGN), bluebird bio (BLUE), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA) and Regeneron Pharmaceuticals (REGN).

Who are Radius Health's key executives?

Radius Health's management team includes the folowing people:
  • Mr. Jesper Høiland, Pres, CEO & Director (Age 59)
  • Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)
  • Mr. Brent Hatzis-Schoch J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Brian Nicholas Harvey, Advisor (Age 58)
  • Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board

Who are Radius Health's major shareholders?

Radius Health's stock is owned by many different of retail and institutional investors. Top institutional shareholders include BB Biotech AG (14.73%), FMR LLC (2.17%), Eversept Partners LP (1.21%), Northern Trust Corp (1.08%), Geode Capital Management LLC (1.00%) and Geode Capital Management LLC (1.00%). Company insiders that own Radius Health stock include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland, Jessica Hopfield, Jose Carmona and Joseph Francis Kelly. View Institutional Ownership Trends for Radius Health.

Which institutional investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, MetLife Investment Advisors LLC, TD Asset Management Inc., New York State Common Retirement Fund, Bank of America Corp DE, United Services Automobile Association and Northern Trust Corp. View Insider Buying and Selling for Radius Health.

Which institutional investors are buying Radius Health stock?

RDUS stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, BB Biotech AG, Two Sigma Investments LP, Pura Vida Investments LLC, Knott David M, Geode Capital Management LLC, Geode Capital Management LLC and Jane Street Group LLC. Company insiders that have bought Radius Health stock in the last two years include Brent Hatzis-Schoch, Growth N V Biotech, Jesper Hoiland, Jessica Hopfield, Jose Carmona and Joseph Francis Kelly. View Insider Buying and Selling for Radius Health.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $18.43.

How big of a company is Radius Health?

Radius Health has a market capitalization of $843.17 million and generates $99.24 million in revenue each year. The biopharmaceutical company earns $-221,340,000.00 in net income (profit) each year or ($4.88) on an earnings per share basis.

What is Radius Health's official website?

The official website for Radius Health is

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]

MarketBeat Community Rating for Radius Health (NASDAQ RDUS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  428 (Vote Outperform)
Underperform Votes:  302 (Vote Underperform)
Total Votes:  730
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel